Immunosurveillance of Virus-induced Tumors
- C.J.M. Melief*,
- W.L.E. Vasmel*,
- R. Offringa†,
- E.J.A.M. Sijts*,
- E.A. Matthews*,
- P.J. Peters‡,
- R.H. Meloen§,
- A.J. van der Eb†, and
- W.M. Kast*
- *Division of Immunology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Huis, 1066 CX Amsterdam; †Sylvius Laboratory, University of Leiden, Leiden; ‡Laboratory of Cell Biology, Center for Electron Microscopy, University of Utrecht, Utrecht; §Central Veterinary Institute, Lelystad, The Netherlands
This extract was created in the absence of an abstract.
Excerpt
T-cell immunity is of paramount importance in the defense against viruses and virus-induced tumors (Klein 1973; Zinkernagel and Doherty 1979; Doherty 1985; Kast et al. 1986; Zijlstra and Melief 1986). Virus-induced tumors can evade T-cell immunity by down-regulation of class I major histocompatibility complex (MHC) expression (Bernards et al. 1983; Schrier et al. 1983; Hui et al. 1984) or by failure to express viral antigens (Green 1983; van der Hoorn et al. 1985; Vas-mel et al. 1989). The relevance of class I MHC down-regulation in evasion of T-cell immunity by adenovirus type 12 (Adl2) early region 1 (El)-induced tumors (Bernards et al. 1983; Schrier et al. 1983) is supported by our recent demonstration of eradication of large Ad5 E1-induced tumors, without down-regulated class I MHC expression, by cloned E1-specific cytotoxic T lymphocytes (CTL) (Kast et al. 1989). In this paper, we review the evidence from our laboratory for the remarkable...
